- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00187798
Impact of Genetics on Metformin Pharmacokinetics
Study Overview
Status
Intervention / Treatment
Detailed Description
Twin studies have long been a valuable tool for examining the relative role of environment and heredity in health issues such as disease and drug response. For example, twin studies in the 1960's and 1970's showed for the first time that variability in the elimination of many drugs was largely influenced by heredity. Monozygotic twin pairs showed little variability in the elimination of various drugs while dizygotic twin pairs, sharing only about one half of their genes, showed much greater variability. It is now known that the some of the variability in drug elimination observed in dizygotic twins was due to genetic differences in drug metabolizing enzymes, such as the cytochrome P450's. However, genetic variation in other genes, such as membrane transporters may also contribute to variability in drug response.
Membrane transporters play multiple roles in the body; they help to maintain cellular homeostasis through import and export mechanisms and also play an important role in drug response, affecting both the pharmacokinetics and pharmacodynamics of drugs. Animal studies using mice genetically deficient in drug transporters and reports of drug interaction studies involving transporter substrates have provided convincing evidence that the level of function of several important drug transporters is an important determinant of drug response.
The current study will examine differences in the renal clearance of metformin in monozygotic and dizygotic twin pairs. Metformin is an antidiabetic drug that has no significant hepatic metabolism and is actively secreted by the kidneys. Studies in our lab have shown that metformin is a substrate of the human organic cation transporter, hOCT2, which appears to be a major transporter involved in the renal secretion of cationic drugs. Data in the literature indicate that there is substantial variation in the net secretory clearance of metformin in normal, healthy volunteers. In five healthy volunteers, the ratio of renal clearance to creatinine clearance ranged from 1.5 to 4.2, nearly a 3-fold variation. We hypothesize that genetic variation in secretory transporters in the kidney, like hOCT2, may be responsible for the inter-individual differences in the secretory clearance of metformin and other drugs. Studies examining renal clearance of metformin in monozygotic and dizygotic twins will allow us to better understand the influence of heredity on variation in renal elimination. Furthermore, genotyping monozygotic and dizygotic twin pairs with significant differences in renal clearance of metformin may give us insight into the genes responsible for this variability.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California San Francsico
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Part of either a monozygotic or dizygotic twin pair.
- Healthy (by medical history and laboratory values).
- Between 18 and 40 years old.
Exclusion Criteria:
- Taking regular medication other than vitamins.
- Individuals with anemia (hemoglobin < 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL Pregnant at time of study.
- Diagnosis of hypoglycemia, phlebitis and/or stroke will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Metformin
Metformin HCl
|
Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To compare metformin pharmacokinetics in monozygotic and dizygotic twin pairs.
Time Frame: 24 hours
|
Comparing renal clearance of metformin in monozygotic and dizygotic twins will allow us to better understand the influence of heredity on variation in renal elimination.
Furthermore, genotyping renal transporter genes in monozygotic and dizygotic twin pairs with significant differences in renal clearance of metformin may give us insight into the genes responsible for this variability.
|
24 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kathleen Giacomini, PhD, University of California San Francsico
Publications and helpful links
General Publications
- Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics. 2003 Sep;13(9):581-4. doi: 10.1097/00008571-200309000-00007.
- Leabman MK, Huang CC, Stryke D, Johns SJ, Kawamoto M, Ferrin TE, DeYoung J, Taylor TR, De La Cruz M, Herskowitz I, Giacomini KM. PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2). Pharmacol Rev. 2003 Sep;55(3):399. doi: 10.1124/pr.55.3.6. Epub 2003 Jul 17. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 928
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Other Conditions That May Be A Focus of Clinical Attention
-
Mahidol UniversityCompletedOther Conditions That May Be A Focus of Clinical AttentionThailand
-
University of Lausanne HospitalsCompletedOther Conditions That May Be A Focus of Clinical AttentionSwitzerland
-
Philips HealthcareCompletedOther Conditions That May Be A Focus of Clinical AttentionIsrael
-
University of California, San FranciscoCompletedOther Conditions That May Be A Focus of Clinical AttentionUnited States
-
University of California, San FranciscoCompletedOther Conditions That May Be A Focus of Clinical AttentionUnited States
-
University of California, San FranciscoWithdrawnOther Conditions That May Be A Focus of Clinical AttentionUnited States
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Associação Fundo de Incentivo...Completed
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedOther Condition That May be a Focus of Clinical AttentionBrazil
-
Baskent University Ankara HospitalUnknownTo Investigate the Incidence and Causes of Awareness During General Anesthesia | To Investigate the of Dreaming During Anesthesia | To Investigate the Intra-operative Experiences of Patients Who Report Awareness | To Investigate the Risk Factors That May be Associated With Awareness | To... and other conditionsTurkey
-
Universidad Autonoma de Ciudad JuarezNot yet recruitingReduction in Mental Health and Suicide Are the Focus of Interest | Four Assessment Time Points Would be Used to Monitor Participants Through a Laid Down ConditionsMexico
Clinical Trials on Metformin HCl
-
LG Life SciencesCompleted
-
Bristol-Myers SquibbCompletedDiabetes Mellitus, Non-Insulin-DependentUnited States
-
Daiichi Sankyo, Inc.TerminatedType 2 Diabetes MellitusUnited States
-
LG Life SciencesUnknown
-
LG Life SciencesCompleted
-
LG Life SciencesCompleted
-
Bristol-Myers SquibbCompletedDiabetes Mellitus, Non-Insulin-DependentUnited States
-
LG ChemCompletedHealthy Male VolunteersKorea, Republic of
-
Boston Children's HospitalCompleted
-
Children's Hospital Los AngelesTerminatedHyperglycemia | Diabetes Mellitus | Insulin Resistance | Acute Lymphoblastic LeukemiaUnited States